Parkinson's DiseaseIt is the second most common neurodegenerative disease, characterized pathologically by the progressive loss of dopaminergic neurons in the substantia nigra of the midbrain, leading to core symptoms such as bradykinesia, resting tremor, rigidity, and postural instability. Current standard clinical treatments primarily involve levodopa as a dopamine neurotransmitter replacement, supplemented by symptomatic interventions such as dopamine receptor agonists, monoamine oxidase B inhibitors, and deep brain stimulation. However, none of these methods can halt or reverse the ongoing degeneration of neurons. As the disease progresses, patients often experience severe issues such as medication response fluctuations, dyskinesia, worsening non-motor symptoms, and a progressively narrowing therapeutic window. Therefore, developing therapies capable of reconstructing functional dopaminergic neural networks and achieving disease modification or even regenerative repair has become one of the most urgent unmet needs in the field of Parkinson's disease.
In recent years,Induced Pluripotent Stem Cell (iPSC) TechnologyThe breakthrough provides a new path for cell replacement therapy – by reprogramming somatic cells from patients or healthy donors into iPSCs, and then differentiating them into high-purity dopaminergic neuron precursor cells, it is theoretically possible to achieve scalable production and standardized quality control of "off-the-shelf" cellular drugs.
iRegene, a pharmaceutical company developed in ChinaNouvNeu001It is precisely the first allogeneic iPSC-derived cell therapy based on this strategy (Recommended reading:[Wind Vane] iRegene's Chinese-produced Parkinson’s cell therapy product NouvNeu001 Receives FDA Approval for Clinical Trials; Trials in China Also Enter Accelerated Phase). From the mechanism of action, NouvNeu001 is an allogeneic cell therapy derived from iPSCs. Its core concept is not merely to replenish the missing dopamine neurotransmitter but to address and repair the root cause of degenerative disorders. Through ex vivo directed differentiation technology, healthy iPSCs are induced to differentiate into high-purity dopaminergic neuron precursor cells, which are then delivered to the patient's midbrain substantia nigra region via stereotactic transplantation. After transplantation, the cells can survive and mature in the host body and establish functional synaptic connections with existing neural networks, thereby reconstructing physiological dopamine secretion and regulatory rhythms.
On December 22, 2025, NouvNeu001 Injection was granted by the U.S. Food and Drug Administration (FDA)Regenerative Medicine Advanced Therapy (RMAT) Designation, becoming the world's first iPSC chemically induced universal cell therapy product to receive this designation in the field of neurological diseases. Previously, the product had already been grantedFast Track Designation (FTD)Thus, NouvNeu001 has become the world's first iPSC product to simultaneously receive both FDA FTD and RMAT designations to date.
RMAT stands for Regenerative Medicine Advanced Therapy, an accelerated approval pathway established by the 21st Century Cures Act of 2016. It is specifically designed for regenerative medicine therapies, with a focus on significant clinical value, to facilitate their rapid market entry and address unmet medical needs.
Dr. Meng Cai, Chief Medical Officer of iRegeneIndicates:"Receiving RMAT designation is an important regulatory milestone in the development process of NouvNeu001, fully demonstrating its clinical value and innovation. This not only indicates the FDA’s recognition of the product's therapeutic potential for serious unmet medical needs but also provides us with a structured pathway for in-depth and efficient collaboration with regulatory authorities. We will make full use of this qualification to accelerate global multi-center clinical trials, striving to bring this revolutionary therapy to patients worldwide as soon as possible."
Entering 2026, the clinical development of NouvNeu001 continues to advance rapidly. On February 11, 2026, the product completedFirst Patient Dosed in U.S. Phase II Clinical Trial; Following that, on March 16, 2026, the company announced that NouvNeu001 had been completed.All Patients Enrolled in China Phase II Clinical Trial Dosed。
Reviewing the R&D process of NouvNeu001, it has achieved repeated breakthroughs in the field of Parkinson's disease:
On August 3, 2023, NouvNeu001 received approval from China's NMPA to initiate a combined Phase I/II clinical trial in China for moderate to severe Parkinson's disease;
In December 2023, NouvNeu001 officially launched its Phase I clinical trial at the National Center for Geriatrics and Gerontology, Beijing Hospital, Ministry of Health.
In March 2024, the U.S. FDA granted NouvNeu001 special exemption status, recognizing iRegene's breakthrough innovation platform and comprehensive quality system, and exempting NouvNeu001 from related U.S. Pharmacopeia requirements.
In June 2024, the US FDA approved its IND to initiate an international multicenter Phase I clinical trial in the United States and other countries;
In November 2024, NouvNeu001 completed patient enrollment for Phase I clinical trials in China;
In April 2025, NouvNeu001 officially launched the Phase II clinical trial in China;
From April to June 2025, iRegene launched the overseas multi-center Phase I clinical trial of NouvNeu001 in multiple countries;
In July 2025, the first group of patients in the Phase II clinical trial of NouvNeu001 completed dosing;
On August 15, 2025, NouvNeu001 was granted Fast Track Designation (FTD) by the FDA;
On December 22, 2025, NouvNeu001 further received FDA Regenerative Medicine Advanced Therapy (RMAT) designation.
